Structural Insights into HIV-1 Vif-APOBEC3F Interaction. 2016

Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Department of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan.

The HIV-1 Vif protein inactivates the cellular antiviral cytidine deaminase APOBEC3F (A3F) in virus-infected cells by specifically targeting it for proteasomal degradation. Several studies identified Vif sequence motifs involved in A3F interaction, whereas a Vif-binding A3F interface was proposed based on our analysis of highly similar APOBEC3C (A3C). However, the structural mechanism of specific Vif-A3F recognition is still poorly understood. Here we report structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Alanine-scanning analysis of Vif revealed that six residues located within the conserved Vif F1-, F2-, and F3-box motifs are essential for both A3C and A3F degradation, and an additional four residues are uniquely required for A3F degradation. Modeling of the Vif structure on an HIV-1 Vif crystal structure revealed that three discontinuous flexible loops of Vif F1-, F2-, and F3-box motifs sterically cluster to form a flexible A3F interaction interface, which represents hydrophobic and positively charged surfaces. We found that the basic Vif interface patch (R17, E171, and R173) involved in the interactions with A3C and A3F differs. Furthermore, our crystal structure determination and extensive mutational analysis of the A3F C-terminal domain demonstrated that the A3F interface includes a unique acidic stretch (L291, A292, R293, and E324) crucial for Vif interaction, suggesting additional electrostatic complementarity to the Vif interface compared with the A3C interface. Taken together, these findings provide structural insights into the A3F-Vif interaction mechanism, which will provide an important basis for development of novel anti-HIV-1 drugs using cellular cytidine deaminases. OBJECTIVE HIV-1 Vif targets cellular antiviral APOBEC3F (A3F) enzyme for degradation. However, the details on the structural mechanism for specific A3F recognition remain unclear. This study reports structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Three discontinuous sequence motifs of Vif, F1, F2, and F3 boxes, assemble to form an A3F interaction interface. In addition, we determined a crystal structure of the wild-type A3F C-terminal domain responsible for the Vif interaction. These results demonstrated that both electrostatic and hydrophobic interactions are the key force driving Vif-A3F binding and that the Vif-A3F interfaces are larger than the Vif-A3C interfaces. These findings will allow us to determine the configurations of the Vif-A3F complex and to construct a structural model of the complex, which will provide an important basis for inhibitor development.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D043525 Cytosine Deaminase An enzyme which catalyzes the deamination of CYTOSINE resulting in the formation of URACIL. It can also act on 5-methylcytosine to form THYMIDINE. Cytosine Aminohydrolase,Aminohydrolase, Cytosine,Deaminase, Cytosine
D054320 vif Gene Products, Human Immunodeficiency Virus Proteins encoded by the VIF GENES of the HUMAN IMMUNODEFICIENCY VIRUS. HIV vif Gene Product,vif Gene Products, HIV,vif Proteins, Human Immunodeficiency Virus
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D025941 Protein Interaction Mapping Methods for determining interaction between PROTEINS. Interaction Mapping, Protein,Interaction Mappings, Protein,Mapping, Protein Interaction,Mappings, Protein Interaction,Protein Interaction Mappings

Related Publications

Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
May 2024, Nature structural & molecular biology,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
December 2019, Nature structural & molecular biology,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
November 2014, Journal of virology,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
August 2004, Current opinion in immunology,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
January 2013, Nature communications,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
February 2010, The journal of medical investigation : JMI,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
September 2008, Journal of molecular biology,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
July 2023, Nature communications,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
September 2014, Trends in biochemical sciences,
Masaaki Nakashima, and Hirotaka Ode, and Takashi Kawamura, and Shingo Kitamura, and Yuriko Naganawa, and Hiroaki Awazu, and Shinya Tsuzuki, and Kazuhiro Matsuoka, and Michiko Nemoto, and Atsuko Hachiya, and Wataru Sugiura, and Yoshiyuki Yokomaku, and Nobuhisa Watanabe, and Yasumasa Iwatani
November 2013, Open biology,
Copied contents to your clipboard!